Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dapsone Formulation A · 1 trial · 1 indication
Cmax is the maximum plasma level following multiple doses of dapsone. Plasma is the liquid component of the blood in which the blood cells are suspended.
| Arm | Type | Description |
|---|---|---|
| Dapsone Formulation A | EXPERIMENTAL | Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days. |
| Dapsone Formulation B | EXPERIMENTAL | Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days. |
| Dapsone Formulation C | EXPERIMENTAL | Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days. |
| Dapsone 5% Gel | ACTIVE_COMPARATOR | Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days. |
| Name | Type | Description |
|---|---|---|
| Dapsone Formulation A | DRUG | Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days. |
| Dapsone Formulation B | DRUG | Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days. |
| Dapsone Formulation C | DRUG | Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days. |
| Dapsone 5% Gel | DRUG | Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days. |
Inclusion Criteria: * Diagnosis of acne vulgaris * Willing to avoid excessive or prolonged exposure to ultraviolet light (e.g., sunlight, tanning beds) throughout the study * If male, the subject must agree to shave the facial treatment area and agree to maintain his routine shaving regimen for the...
Dapsone Formulation A is an investigational small molecule being developed for the treatment of acne vulgaris, a common skin condition characterized by pimples and inflammation. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Dapsone Formulation A is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical research to evaluate the safety and pharmacokinetics of this investigational drug.
Dapsone Formulation A is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The Phase 1 trial has been completed, and the drug remains under evaluation for the treatment of acne vulgaris.
Dapsone Formulation A has been studied in one completed Phase 1 clinical trial with the identifier NCT01773122, titled "Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris." The trial enrolled 77 participants in the United States and was randomized, double-blind, and active-controlled.
Dapsone Formulation A is a specific formulation of dapsone, a small molecule drug. While dapsone itself is a known medication, this particular formulation is being investigated as a new treatment for acne vulgaris and is currently in Phase 1 clinical development.